Synthesis and Assembly of Hepatitis B Virus-Like Particles in a Pichia pastoris Cell-Free System

被引:34
作者
Spice, Alex J. [1 ,2 ]
Aw, Rochelle [1 ,2 ]
Bracewell, Daniel G. [3 ]
Polizzi, Karen M. [1 ,2 ]
机构
[1] Imperial Coll London, Dept Chem Engn, London, England
[2] Imperial Coll London, Imperial Coll Ctr Synthet Biol, London, England
[3] UCL, Dept Biochem Engn, London, England
来源
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY | 2020年 / 8卷 / 08期
基金
英国工程与自然科学研究理事会;
关键词
cell-free protein synthesis; virus-like particles; Pichia pastoris; synthetic biology; hepatitis B core antigen; FREE PROTEIN-SYNTHESIS; CORE PARTICLES; ESCHERICHIA-COLI; TRANSLATION SYSTEM; CAPSIDS; EXPRESSION; VACCINES; THERMODYNAMICS; NANOPARTICLES; NANOREACTORS;
D O I
10.3389/fbioe.2020.00072
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Virus-like particles (VLPs) are supramolecular protein assemblies with the potential for unique and exciting applications in synthetic biology and medicine. Despite the attention VLPs have gained thus far, considerable limitations still persist in their production. Poorly scalable manufacturing technologies and inconsistent product architectures continue to restrict the full potential of VLPs. Cell-free protein synthesis (CFPS) offers an alternative approach to VLP production and has already proven to be successful, albeit using extracts from a limited number of organisms. Using a recently developed Pichia pastoris-based CFPS system, we have demonstrated the production of the model Hepatitis B core antigen VLP as a proof-of-concept. The VLPs produced in the CFPS system were found to have comparable characteristics to those previously produced in vivo and in vitro. Additionally, we have developed a facile and rapid synthesis, assembly and purification methodology that could be applied as a rapid prototyping platform for vaccine development or synthetic biology applications. Overall the CFPS methodology allows far greater throughput, which will expedite the screening of optimal assembly conditions for more robust and stable VLPs. This approach could therefore support the characterization of larger sample sets to improve vaccine development efficiency.
引用
收藏
页数:11
相关论文
共 78 条
  • [1] Protein expression in Pichia pastoris: recent achievements and perspectives for heterologous protein production
    Ahmad, Mudassar
    Hirz, Melanie
    Pichler, Harald
    Schwab, Helmut
    [J]. APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2014, 98 (12) : 5301 - 5317
  • [2] ANDERSON CW, 1983, METHOD ENZYMOL, V101, P635
  • [3] Biosensor-assisted engineering of a high-yield Pichia pastoris cell-free protein synthesis platform
    Aw, Rochelle
    Polizzi, Karen M.
    [J]. BIOTECHNOLOGY AND BIOENGINEERING, 2019, 116 (03) : 656 - 666
  • [4] Playing catch-up with Escherichia coli: using yeast to increase success rates in recombinant protein production experiments
    Bill, Roslyn M.
    [J]. FRONTIERS IN MICROBIOLOGY, 2014, 5
  • [5] A miRNA-responsive cell-free translation system facilitates isolation of hepatitis C virus miRNP complexes
    Bradrick, Shelton S.
    Nagyal, Simardeep
    Novatt, Hilary
    [J]. RNA, 2013, 19 (08) : 1159 - 1169
  • [6] Cell-Free Protein Expression Based on Extracts From CHO Cells
    Broedel, Andreas K.
    Sonnabend, Andrei
    Kubick, Stefan
    [J]. BIOTECHNOLOGY AND BIOENGINEERING, 2014, 111 (01) : 25 - 36
  • [7] Escherichia coli-based cell-free synthesis of virus-like particles
    Bundy, Bradley C.
    Franciszkowicz, Marc J.
    Swartz, James R.
    [J]. BIOTECHNOLOGY AND BIOENGINEERING, 2008, 100 (01) : 28 - 37
  • [8] Tobacco BY-2 cell-free lysate: an alternative and highly-productive plant-based in vitro translation system
    Buntru, Matthias
    Vogel, Simon
    Spiegel, Holger
    Schillberg, Stefan
    [J]. BMC BIOTECHNOLOGY, 2014, 14
  • [9] Cell-free protein synthesis: Applications come of age
    Carlson, Erik D.
    Gan, Rui
    Hodgman, C. Eric
    Jewett, Michael C.
    [J]. BIOTECHNOLOGY ADVANCES, 2012, 30 (05) : 1185 - 1194
  • [10] Virus-like particles-flexible platforms for vaccine development
    Chackerian, Bryce
    [J]. EXPERT REVIEW OF VACCINES, 2007, 6 (03) : 381 - 390